XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 22,725,383 $ 29,163,200
Restricted cash 0 5,004,789
Marketable securities 27,597,303 25,916,681
Prepaid and other current assets 1,228,898 1,312,503
Total current assets 51,551,584 61,397,173
Property and equipment, net 98,123 256,905
Other assets 442,806 1,721,604
Total assets 52,092,513 63,375,682
Current Liabilities    
Accounts payable 505,665 1,343,089
Accrued liabilities 5,299,075 7,810,948
Notes payable, current 23,289 159,180
Total current liabilities 5,828,029 9,313,217
Other long-term liabilities 2,797,933 3,872,679
Total liabilities 8,625,962 13,185,896
Commitments and Contingencies
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2018 and December 31, 2017, respectively 100 100
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,735,361 and 9,483,911 shares at June 30, 2018 and December 31, 2017, respectively 9,735 9,484
Additional paid-in capital 435,337,922 433,044,209
Treasury stock, at cost; 11,080 shares at June 30, 2018 and December 31, 2017 (707,637) (707,637)
Accumulated deficit (390,869,059) (381,810,109)
Accumulated other comprehensive loss (31,091) (27,978)
Total Caladrius Biosciences, Inc. stockholders' equity 43,739,970 50,508,069
Noncontrolling interests (273,419) (318,283)
Total equity 43,466,551 50,189,786
Liabilities and Equity, Total $ 52,092,513 $ 63,375,682